Docket No.: 50179-086

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Thomas Charles ELLEMAN, et al.

Serial No.:

Group Art Unit:

Filed: November 29, 2000

Examiner:

For:

METHOD OF DESIGNING AGONISTS AND ANTAGONISTS TO EGF

RECEPTOR FAMILY

INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner of Patents and Trademarks Washington, D. C. 20231


Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached form PTO-1449. It is respectfully requested that the references be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed with the application and no certification or fee is required.

A copy of the foreign search report is attached for the Examiner's information. Please note this is a PCT application in the entry of the National Phase in the U.S. and

Serial No.:



copies of the references cited were transmitted by WIPO and are believed to be in the file of the above identified application and readily available to the Examiner. However, to ensure that these references are available to the Examiner, we are providing copies of these references herewith. Therefore it is believed that Applicants have met all requirements regarding duty of disclosure under 37 CFR 1.56. Acknowledgement and consideration of these documents are respectfully requested.

Respectfully submitted,

MCDERMOTT, WILL & EMERY

Robert L. Price

Registration No. 22,685

600 13th Street, N.W. Washington, DC 20005-3096

(202) 756-8000 RLP:dtb

Date: November 29, 2000 Facsimile: (202) 756-8087